Clinical and pharmacokinetic study of gemcitabine (GEM) - oxaliplatin (OXA) association in metastatic or locally advanced pancreatic adenocarcinoma.

被引：0
|
作者：
Airoldi, M
Cattel, L
Passera, R
Micari, C
Ferrarato, E
Zanon, C
机构：
[1] Osped San Giovanni Ant Sede, Turin, Italy
[2] Univ Turin, Fac Farm, Turin, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2059
引用
收藏
页码：141S / 141S
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis
    Ventriglia, J.
    Laterza, M. M.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Pompella, L.
    Pappalardo, A.
    Orditura, M.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer
    Sahora, Klaus
    Kuehrer, Irene
    Eisenhut, Axel
    Akan, Belgin
    Koellblinger, Claus
    Goetzinger, Peter
    Teleky, Bela
    Jakesz, Raimund
    Peck-Radosavljevic, Markus
    Ba'ssalamah, Ahmed
    Zielinski, Christoph
    Gnant, Michael
    SURGERY, 2011, 149 (03) : 311 - 320
  • [43] Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine
    Ploquin, Anne
    Truant, Stephanie
    Piessen, Guillaume
    Vuagnat, Perrine
    Baldini, Capucine
    Cattan, Stephane
    Hebbar, Mohamed
    IN VIVO, 2017, 31 (04): : 731 - 735
  • [44] Immunotherapy engagement in pancreatic adenocarcinoma: Provisional results of iLSTA study- Durvalumab, LSTA1 (certepetide), gemcitabine, and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma.
    Dean, Andrew Peter
    Johansson, Mikael
    Yusoff, Ian
    Rao, Samarth
    Sparrow, Susan
    Kumarasinghe, Priyanthi
    Navadgi, Suresh
    Watanabe, Yuki
    Webber, Laurence
    Grew, Jenny
    Fitzgerald, Shane
    Comito, Olivia Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [45] Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study
    Karasek, P
    Skacel, T
    Kocakova, I
    Bednarik, O
    Petruzelka, L
    Melichar, B
    Bustova, I
    Spurny, V
    Trason, T
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (04) : 581 - 586
  • [46] Biologically optimized schedule of gemcitabine and nab-paclitaxel regimen in metastatic pancreatic adenocarcinoma.
    Abushahin, Laith I.
    Noonan, Anne M.
    Hays, John L.
    Malalur, Pannaga G.
    Manne, Ashish
    Jin, Ning
    Mittra, Arjun
    Elkhatib, Rifat T.
    Roychowdhury, Sameek
    Williams, Terence Marques
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study
    Alberts, SR
    Townley, PM
    Goldberg, RM
    Cha, SS
    Sargent, DJ
    Moore, DF
    Krook, JE
    Pitot, HC
    Fitch, TR
    Wiesenfeld, M
    Mailliard, JA
    ANNALS OF ONCOLOGY, 2003, 14 (04) : 580 - 585
  • [48] A phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma.
    Duck, LR
    Sempoux, C
    Honhon, B
    Coster, B
    Coche, JC
    Kerger, J
    Canon, JL
    Humblet, Y
    Scalliet, P
    Machiels, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 258S - 258S
  • [49] Combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma - a Phase Ib/IIa study
    Schultheis, B.
    Strumberg, D.
    Kuhlmann, J.
    Wolf, M.
    Link, K.
    Seufferlein, T.
    Kaufmann, J.
    Gebhardt, F.
    Khan, M.
    Pelzer, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 64 - 64
  • [50] A phase 1/2 study of combination therapy of ivaltinostat, gemcitabine, and erlotinib in patients with unresectable, locally advanced and metastatic pancreatic adenocarcinoma
    Jo, J.
    Lee, H.
    Park, S.
    Chung, D.
    Cho, S.
    Cha, H.
    Cho, J.
    Song, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S211 - S211
12345